Deeply invasive candidiasis

Luis Ostrosky-Zeichner, John H. Rex, John Bennett, Bart Jan Kullberg

Research output: Contribution to journalReview articlepeer-review

Abstract

The incidence of invasive candidiasis is on the rise because of increasing numbers of immunocompromised hosts and more invasive medical technology. Recovery of Candida spp from several body sites in a critically ill or immunocompromised patient should raise the question of disseminated disease. Although identification to the species level and antifungal susceptibility testing should guide therapy, at this time amphotericin B preparations are the usual initial therapy for severe life-threatening disease. Azole therapy has an expanding body of evidence that proves it is as effective as and safer than amphotericin B therapy. Some forms of candidiasis (eg, those with ocular, bone, or heart involvement) require a combined medical and surgical approach.

Original languageEnglish (US)
Pages (from-to)821-835
Number of pages15
JournalInfectious disease clinics of North America
Volume16
Issue number4
DOIs
StatePublished - Dec 2002

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Deeply invasive candidiasis'. Together they form a unique fingerprint.

Cite this